Skip to main content
Fig. 3 | Journal of Neuroinflammation

Fig. 3

From: Administration of anti-ERMAP antibody ameliorates Alzheimer’s disease in mice

Fig. 3

Administration of anti-ERMAP mAb attenuates AD pathology. AC 3XTg-AD mice were injected with anti-ERMAP mAb, or control isotype Ab (50 µg per mice) once a week. Three and a half months later, the mice were examined for AD brain pathology, and E soluble Aβ levels. The brain sections were immunostained for Aβ (in red), GFAP (in green) and Hoechst nuclear staining. Mean Aβ area and plaque numbers in the hippocampal DG and the cortex fifth layer, and GFAP immunoreactivity in the hippocampus were assessed. A Representative immunofluorescent images, and BD quantitative analysis of Aβ and GFAP. E Levels of soluble Aβ1–40 and Aβ1–42 in the cerebral brain parenchyma of the mice were quantified by ELISA. F, G 14-month-old female APP/PS1 mice were injected with anti-ERMAP mAb, or isotype Ab (50 µg) once a week. Two months later, the mice were evaluated for brain pathology. F Representative immunofluorescent images, and G quantitative analysis of Aβ. The data are expressed as mean ± SD from one of three independent experiments with similar results (5 to 8 mice per group per experiment). *P < 0.05 versus control group

Back to article page